Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Assets (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Non-Current Assets for 4 consecutive years, with $11.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets fell 76.92% year-over-year to $11.7 million, compared with a TTM value of $102.9 million through Sep 2025, down 54.9%, and an annual FY2024 reading of $44.2 million, down 30.54% over the prior year.
  • Non-Current Assets was $11.7 million for Q3 2025 at Atara Biotherapeutics, down from $12.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $89.1 million in Q2 2022 and bottomed at $11.7 million in Q3 2025.
  • Average Non-Current Assets over 4 years is $59.5 million, with a median of $63.6 million recorded in 2023.
  • The sharpest move saw Non-Current Assets dropped 6.02% in 2023, then crashed 77.89% in 2025.
  • Year by year, Non-Current Assets stood at $81.3 million in 2022, then dropped by 21.77% to $63.6 million in 2023, then tumbled by 30.54% to $44.2 million in 2024, then tumbled by 73.45% to $11.7 million in 2025.
  • Business Quant data shows Non-Current Assets for ATRA at $11.7 million in Q3 2025, $12.1 million in Q2 2025, and $34.9 million in Q1 2025.